Download MendeleyCharacterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases.
Guo, M., Dai, S., Wu, D., Duan, Y., Li, J., Qu, L., Jiang, L., Chen, Z., Chen, X., Chen, Y.(2020) Bioorg Med Chem Lett 34: 127757-127757
- PubMed: 33359446
- DOI: https://doi.org/10.1016/j.bmcl.2020.127757
- Primary Citation of Related Structures:
6L8L - PubMed Abstract:
Ibrutinib is a BTK-targeted irreversible inhibitor. In this study, we demonstrate that ibrutinib potently inhibits SRC activity in a non-covalent manner via mass spectrometry and crystallography. The S345C mutation renders SRC to bind covalently with ibrutinib, and restores the potency of ibrutinib against the gatekeeper mutant. The co-crystal structure of ibrutinib/SRC shows Ser345 of SRC did not form covalent bond with ibrutinib, leading to a decrease of potency and loss of the ability to overcome the gatekeeper mutation of SRC. The X-ray crystallographic studies also provide structural insight into why ibrutinib behaves differently against gatekeeper mutants of different kinases.
- Department of Oncology, NHC Key Laboratory of Cancer Proteomics, Laboratory of Structural Biology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Organizational Affiliation:
